Trans Global Group, Inc. (OTC: TGGI) is drifting towards established support level of $0.007, a support level it has held a number of times before, it hit $0.007 in January and back in October it traded as low as $0.0065 but never closed under $0.007. TGGI is a fully reporting reverse merger play with global ambitions and a significant investor following. Mr. Chen Ren Feiyang currently owns the controlling block of TGGI and along with TGGI president, Mr. Tang Jiacheng the two have long been very public about their intentions for going to a national market and forming a global enterprise. While it may seem like little is happening, there are things happening they put out the 10-12G/A on June 8.
Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars including TSNP/HMBL which we first reported on at $0.003. TGGI also has some in common with TXTM in that both of these RM plays has a large following that waited patiently for many months; for TXTM when the RSAMMD RM was finally announced on a Sunday, the stock ran 1000% the following week and much of the stocks ability to maintain momentum for 5 days straight in a terrible market (a week when the Dow was down over 700 points on 3 different days) was due to its large and loyal following.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Trans Global Group Inc (OTCMKTS: TGGI) is a Delaware holding company that plans to conduct substantially all of its operations and business in China through PRC based subsidiaries. On April 29, 2021, ONE DAY after the HK requirements for filings (SURGICAL) Chen Ren executed the Change of Control documents for $TGGI. In it, they stated CLEAR intentions to acquire liquor companies in China. Chen Ren is now the controlling shareholder of TGGI having purchased control for $150,000.
The ambitious new CEO and controlling shareholder of the Company Chen Ren is the founder and owner of Zuixiangui wines which produces over 4,000 tons (11M 1 Liter bottles) annually using patented methods of production on an operations site of more than 300 acres. It is expected that Zuixiangui wines will reverse merge into TGGI. Chen’s passion for wine matched his dreams of becoming a public company and he has made clear his intentions to one day list TGGI on the big boards.
Chen Ren was a famous singer/entertainer in his earlier years. Amongst his many songs/albums, he made numerous songs about wine. He dreamed of making a specific wine and sharing it with the world. Chen’s passion for wine matched his dreams of becoming a NASDAQ company and he has made clear his intentions to one day list TGGI on the big boards. Mr. Ren is the founder and owner of Zuixiangui wines which produces over 4,000 tons (11M 1 Liter bottles) annually using patented methods of production on an operations site of more than 300 acres. It is expected that Zuixiangui wines will reverse merge into TGGI. Zuixiangui has also been making some big moves recently Shaanxi Seeds and Hunan Pharmaceuticals both established business in China. They also announced an incredibly strategic and exciting contract with Yijulian E-commerce Co.
To Find out the inside Scoop on TGGI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Everything below is highly speculative, none of this information has been released by the Company. Below is a twitter thread from Paul Seo. Why are we posting this information? because there is not a lot of official information Coming from the Company however this due diligence has been compiled by TGGI investors and the rest of the TGGI community sees it so this is relevant.
Chen Ren was a famous singer/entertainer in his earlier years. Amongst his many songs/albums, he made numerous songs about wine. He dreamed of making a specific wine and sharing it with the world.
$TGGI: CHAPTER 2: 🍷 ZUIXIANGUI WINES 🍷
Formed 08/2019, it produces over 4,000 tons (11M 1 Liter bottles) annually using patented methods of production on an operations site of more than 300 acres. 11M X $30USD (wholesale) = $33M revenue (CONSERVATIVE!)
$TGGI: CHAPTER 3: ✨ DREAMS OF NASDAQ ✨
Chen’s passion for wine matched his dreams of becoming a NASDAQ company. He began this journey by identifying and purchasing $TGGI in 09/2020 for $150,000. ALL filings prior to Q3 2020 are now irrelevant to $TGGI.
$TGGI: CHAPTER 4: 📈 ZUIXIANGUI INT. HOLDINGS 📈
$TGGI PPS increased 10000% from .0001 (09/2020) to .01 (03/2021) upon the appearance of ZIH, formed 03/22/2021. At this point in the story, we could only assume the nature of holding companies: GROWTH through M&As.
$TGGI: CHAPTER 5: 💯 OTC FINALIZED 💯
On April 29, 2021, ONE DAY after the HK requirements for filings (SURGICAL) Chen executed the Change of Control documents for $TGGI. In it, they stated CLEAR intentions to acquire liquor companies in China. ‼️
$TGGI: CHAPTER 6: 💰 ZIH 2 💰
On May 15, 2021, ZIH reported securing 46 MILLION USD in advertising 💵! Alresdy successful in Shenzhen market, it will use 100-300K to support dealers in new markets! They need to produce A LOT more 🍷 than in CHAPTER 2.
$TGGI: CHAPTER 7: 📣 PLOT TWIST 📣
On June 19, ZuiXianGui announced Acquisitions of 2 HUGE Companies:
Shaanxi Seeds
Hunan Pharmaceuticals
They also announced an incredibly strategic and exciting contract with Yijulian E-commerce Co.
$TGGI: CHAPTER 7: 🌱 SHAANXI SEED 🌱
Shaanxi is a massive agricultural area. Its success is important enough to warrant visits from Pres. Xi JinPing! It’s been in business for over 15 years, accounting for 50% of ALL seed production for southern Shaanxi Province!
$TGGI: CHAPTER 8: 👨⚕️ HUNAN PHARMACEUTICAL 👩⚕️
While we weren’t able to find reported revenues for Shaanxi Seed, we were able to DD figures for Hunan. Over 30M USD revenue in 2019! With their main product being hand sanitizer, consider revenues during COVID. 🙏🙏🙏
$TGGI: CHAPTER 9: 🌊 SOUTHSEA GLOBAL 🌊
The June PR on ZIH WeChat revealed a presentation slide. In it, the umbrella organization was discovered – Southsea Global. This entity was incorporated in the British Virgin Islands 01/26/21.
$TGGI: CHAPTER 9A – BVI
We now know WHY the BVI entity was created BEFORE (Jan 2021) ZuiXianGui International Holdings (March 2021). Because it is the FOUNDING and OWNING entity of ZIH!!! SURGICAL.
$TGGI: CHAPTER 10: 📜 MERGER COMPLETE?!?! 📜
In hindsight from DD discovered more recently… On January 21, 2021, 5 days prior to the BVI entity creation of Southsea Global, Chen Ren and Tang Jiacheng sat down and signed Mergers and Reorganization documents!
$TGGI: CHAPTER 11 🎥 TANG JIACHENG 🎥
Who is he and why does he get a HUGE seat at the table? He OWNS a MEDIA COMPANY:
✨ Advertising
✨ Connections
✨ Experience
🧠: IMO, he was responsible for securing the 46M of investment funds for HIS company in May!
$TGGI: CHAPTER 13 👀 GELECY 👀
Other than owning a company that’s a mash-up of GOOGLE, FACEBOOK, etc., look at everything else he is involved in! One is GELECY, which is listed on the $TGGI website! HELLOOOO! You read below. I’m getting tired now. 😇
$TGGI: FOOTNOTE 1 💲 BUYBACK THEORY 💲
From April to July, BILLIONS of shares in underbids EVERY DAY! Streak of green? Underbid! 9.4B volume since Change of Control 4/29. IMO, 2-2.5B shares went to Tang. That’s 25-35% of the float locked up! Trades thin doesn’t it?!?·
$TGGI: FOOTNOTE 2
UNDERBIDS STOPPED THE DAY AFTER THE Q2 reports for 2021 were submitted!!!
✅: SURGICAL!
$TGGI: FOOTNOTE 3
Significance of merging a BVI entity into $TGGI are multi-faceted:
✅: Tax Savings
✅: Move intellectual property into umbrella company
✅: shareholders can hold shares in BVIs… 1069 beneficial shareholders already for $TGGI!
✅: Um, yeah. Tax savings!
$TGGI: FOOTNOTE 4 ⚠️ SEC AMENDMENTS ⚠️
Given changes to take place on brokerages in early Sept., invest in PINK current & proven Managnent! $TGGI has verified their profile 3 times in 2021. They file on time in a minimum of 3 countries! Highest ROI potential!
$TGGI: some interesting P/E info in the post/ article screenshot below from a few days ago. 💥 PE ratios are higher than I thought for Baijiu. 🔥 Also mentions Pharmaceutical high PE Verify your own data, the above is my opinion. https://t.co/YdNtqVUF0apic.twitter.com/Zpthu28reC
TGGI has a lot of bashers putting in overtime telling you to sell immediately and they are much more persistent than the longs, there is a motive behind this. No one follows stocks they are not going to buy and there are millions of investment opportunities out there. Why are they wasting all this time on TGGI under a penny, why are they so insistent you sell your TGGI a few tenths of a penny over established support levels? They are not there to help you or warn you, and they certainly have ulterior motives. I can tell you from many years of experience in microcaps, some of the most bashed stocks I ever saw were the ones that made the biggest runs. But TGGI is a lotto play and anything is liable to happen here but as far as lotto plays go this is a pretty good one, this is an SEC filer. We will be updating on TGGI when more details emerge so make sure you are subscribed to Microcapdaily so you dont miss out.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in TGGI either long or short and we have not been compensated for this article
Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.
Latest Changes:
Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.
This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Standard Of Care:
Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.
However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).
Drug-eluting biomatrix (DEB):
Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.
The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.
For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.
DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.
Post-mastectomy Breast Reconstruction:
On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.
What’s next:
As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.
We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.
The Release:
When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.
To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.
The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”
The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.
So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.
Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.
We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.
Background:
The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.
Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Allogeneic Cell Therapy:
Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.
Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.
With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.
Latest Release:
The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.
Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.
Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.
A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.
Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.
They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.
We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Boe Rimes
June 25, 2022 at 12:49 am
The article has been updated